Silence develops precision‑engineered small interfering RNA (siRNA) therapeutics that selectively silence disease‑causing genes.
Funding
$120M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases lack effective treatments because existing drugs cannot selectively silence disease-causing genes, leading to limited therapeutic options and unmet medical needs for patients.
Solution
Silence develops precision‑engineered small interfering RNA (siRNA) therapeutics that specifically target and silence disease‑related genes. By leveraging proprietary RNAi design platforms, the company creates molecules with optimized potency, stability, and delivery characteristics. These siRNA candidates progress through preclinical and clinical development pipelines to generate patient‑centric medicines aimed at conditions with few or no approved therapies. The approach seeks to provide efficient, targeted treatment options that address the underlying genetic drivers of disease.
Target Audience
Primary customers are pharmaceutical partners and biotech companies seeking RNAi‑based therapeutic candidates, as well as clinicians treating patients with diseases that have limited or inadequate treatment options.
Features
- Proprietary siRNA design algorithms that maximize target specificity and minimize off‑target effects
- Chemical modification strategies to enhance nuclease resistance and in vivo stability
- Optimized delivery technologies for efficient tissue uptake and cellular entry
- Integrated preclinical and clinical development workflow to accelerate candidate progression
- Biomarker‑driven patient selection to focus on populations with high unmet need